FDA Keeping Surrogate Endpoint For Type 2 Diabetes Agent Approvals

FDA is resoundingly rejecting the suggestion that clinical outcomes be used as the standard of evidence for demonstrating efficacy for anti-diabetic agents, rather than the standard surrogate measure of glycemic control currently used